Thursday September 28, 2023
|
Subscribe
|
Contribute
|
About
|
Access Your Account
|
Register
|
Login
|
Home
|
Issue Archive
|
Featured Reports
|
eBooks
|
BioProcess Insider
|
Multimedia
|
BPI White Papers
|
Webinars
|
Posters
|
BioProcess International Events
|
BioProcess International Conference & Exhibition
|
Cell & Gene Therapy Manufacturing & Commercialization US
|
Well Characterized Biologics & Biological Assays
|
Cell & Gene Therapy Manufacturing & Commercialization Europe
|
BioProcess International Academy
|
Events
Covering the whole development process for the global biotechnology industry
Upstream
Processing
Bioprocessing begins upstream, most often with culturing of animal or microbial cells in a range of vessel types (such as bags or stirred tanks) using different controlled feeding, aerating, and process strategies.
Assays
Biochemicals/Raw Materials
Bioreactors
Cell Culture Media
Expression Platforms
Fermentation
Perfusion Cell Culture
Upstream Contract Services
Upstream Single-Use Technologies
Downstream
Processing
Beginning with harvest of material from a bioreactor, downstream processing removes or reduces contaminants to acceptable levels through several steps that typically include centrifugation, filtration, and/or chromatographic technologies.
Filtration
Separation/Purification
Viral Clearance
Chromatography
Downstream Contract Services
Downstream Single-Use Technologies
Manufacturing
Drug products combine active pharmaceutical ingredients with excipients in a final formulation for delivery to patients in liquid or lyophilized (freeze-dried) packaged forms — with the latter requiring reconstitution in the clinical setting.
Biosimilars
Cell/Gene Therapies
Continuous Bioprocessing
Emerging Therapeutics
Facility Design/Engineering
Fill/Finish
Formulation
Information Technology
MAb
Manufacturing Contract Services
Personalized Medicine
Process Monitoring and Controls
Single Use
Supply Chain
Vaccines
Validation
Analytical
Many technologies are used to characterize biological products, manufacturing processes, and raw materials. The number of options and applications is growing every day — with quality by design (QbD) giving impetus to this expansion.
Culture Development
Cell Line Development
Downstream Development
Downstream Validation
Laboratory Equipment
PAT
Pre-Formulation
Product Characterization
QA/QC
Upstream Development
Upstream Validation
Leachables/Extractables/Particulates
Business
Even as it matures, the biopharmaceutical industry is still a highly entrepreneurial one. Partnerships of many kinds — from outsourcing to licensing agreements to consultancies — help companies navigate this increasingly global business environment.
Careers
CMC Forums
Economics
Intellectual Property
Pre-Clinical and Clinical Trials
Regulatory Affairs
Risk Management
BioRegions
Monday, October 1, 2007
Daily Archives
Polymers for Drugs, Drug–Protein Conjugates, and Gene Delivery
by
BPI Contributor
Trends in Analytical Instrument Qualification
by
BPI Contributor
Transient Gene Silencing in NS/0 Suspension Cell Culture By siRNA
by
BPI Contributor
The Next Five Years — and More
by
BPI Contributor
The FDA Is in Trouble
by
BPI Contributor
Strategy to Identify and Mitigate Risks in Phase 1 Clinical Trials
by
BPI Contributor
Separation and Purification
by
BPI Contributor
Running Fast, Running Lean
by
BPI Contributor
Return to the Dark Side?
by
BPI Contributor
Products, Services, and Literature
by
BPI Contributor
1
2
3
>
Home
Issue Archive
â–¼
Featured Reports
eBooks
BioProcess Insider
Multimedia
â–¼
BPI White Papers
Webinars
Posters
BioProcess International Events
â–¼
BioProcess International Conference & Exhibition
Cell & Gene Therapy Manufacturing & Commercialization US
Well Characterized Biologics & Biological Assays
Cell & Gene Therapy Manufacturing & Commercialization Europe
BioProcess International Academy
Events
